Gil Melmed, MD: Biologics for Inflammatory Bowel Disease

On June 3, 2021, Gil Melmed, MD, led an HCPLive State of the Science expert webinar on the current and future state of inflammatory bowel disease (IBD).

Melmed, Director of Inflammatory Bowel Disease Clinical Research at Cedars-Sinai, was joined by his Cedars-Sinai colleagues Christina Ha, MD, Dermot McGovern, MD, PhD, and Gaurav Syal, MD for a 90-minute program on the following topics:

  • IBD and COVID-19: What have we learned?
  • Biologics for IBD – when, which one, and in whom?
  • Algorithms of Care for IBD
  • Emerging Therapies – the future is bright!

In the clip above, Melmed joins HCPLive for a recap interview on the subjects of the program, highlighting current biologic therapy options for IBD, and what future clinical research should entail.

Related Videos
Cedric Rutland, MD: Exploring Immunology's Role in Molecule Development
Panagis Galiatsatos, MD: Closing the Gap in Lung Cancer Screening
Antonio Anzueto, MD: Advancing Triple-Therapy Inhalers for COPD
Panagis Galiatsatos, MD
Cedric Rutland, MD: Mechanisms Behind Immunology, Cellular Communication
Glenn S. Tillotson, PhD: Treating Immunocompromised Patients With RBX2660
Related Content
© 2023 MJH Life Sciences

All rights reserved.